natgillin/translations-raw huggingface dataset:
A system according to any preceding claim, in which the peripheral region (42, 1042) of the septum (40, 1040) does not form a complete ring around the circular central region (41, 1041), but extends around the central region sufficiently to result in a catastrophic failure around the periphery of the septum in preference to a puncture through the central region of the septum. 
Sustav prema bilo kojem prethodnom zahtjevu, naznačen time da periferno područje (42, 1042) pregrade (40, 1040) ne tvori potpuni prsten oko kružnog središnjeg područja (41, 1041), ali se dovoljno prostire oko središnjeg područja da dovede do katastrofalnog zatajenja na periferiji pregrade umjesto bušenja kroz središnje područje pregrade.
The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is to be administered intraperitoneally, intramuscularly, intravenously, intranasally, subcutaneously, intradermally, or intrathecally. 
Farmaceutski sastav prema patentnom zahtjevu 3, gdje se farmaceutski sastav primjenjuje intraperitonealno, intramuskularno, intravenozno, intranazalno, potkožno, intradermalno ili intratekalno.
The combination for use according to claim 1, wherein the mammalian cell is a pancreatic cell, a liver cell, a gut K cell, a neuron, or an adult stem cell. 
Kombinacija za uporabu prema zahtjevu 1, naznačena time da stanica sisavca je stanica gušterače, stanice jetre, crijevna K stanica, neuronska stanica, ili odrasla matična stanica.
The combination for use according to claim 1, wherein the nucleic acid encoding glucokinase is further comprised in a viral vector, preferably a lentivirus vector. 
Kombinacija za uporabu prema zahtjevu 1, naznačena time da nukleinska kiselina koja kodira glukokinazu nadalje sadrži virusni vektor, poželjno lentivirusni vektor.
The combination for use according to claim 3, wherein the viral vector further comprises a posttranscriptional regulatory element of woodchuck hepatitis virus (WPRE) 3' of the coding sequence. 
Kombinacija za uporabu prema zahtjevu 3, naznačena time da virusni vektor nadalje sadrži posttranskripcijski regulacijski element virusa hepatitisa dabra (WPRE) 3' kodirajuće sekvence.
The combination for use according to claim 1, for use in the treatment of type 1 or type 2 diabetes, the combination comprising: (i) glucokinase expression cassette configured to express a functional glucokinase protein in a pancreatic cell, (ii) a tyrosine phosphatase 1B inhibitor that is an shRNA inhibitor of protein tyrosine phosphatase 1B (PTP1B) or a PTPIB antisense DNA and (iii) a Pdx-1 expression cassette configured to express a functional Pdx-1 protein in a pancreatic cell, the combination being adapted to induce pancreatic beta cells in the pancreas. 
Kombinacija za uporabu prema zahtjevu 1, naznačena time da je za uporabu za liječenje dijabetesa tipa 1 ili tipa 2, te kombinacija sadrži: (i) kasetu za ekspresiju glukokinaze koja je konfigurirana da eksprimira funkcionalni protein glukokinaze u stanici gušterače, (ii) inhibitor tirozin fosfataze 1B koji je shRNA inhibitor proteina tirozin fosfataze 1B (PTP1B) ili PTPIB antisensna DNA i (iii) Pdx-1 ekspresijska kaseta je konfigurirana da eksprimira funkcionalni protein Pdx-1 u stanici gušterače, te je kombinacija prilagođena da inducira beta stanice gušterače u gušterači.
The method of claim 8 wherein the mammalian cell is a pancreatic cell, a liver cell, a gut K cell, a neuron, or an adult stem cell. 
Postupak prema zahtjevu 8 naznačen time da stanica sisavca je stanica gušterače, stanice jetre, crijevna K stanica, neuronska stanica, ili odrasla matična stanica.
The method of claim 8 or claim 9 wherein the mammalian cell is isolated from a subject to be treated with the beta cells or wherein the mammalian cell is heterologous to a subject to be treated with the beta cells. 
Postupak prema zahtjevu 8 ili zahtjevu 9 naznačen time da je stanica sisavaca izolirana iz subjekta koji se tretira s beta stanicama ili pri čemu je stanica sisavca heterologna prema subjektu koji se treba tretirati s beta stanicama.
A method of generating a reconstructed block, comprising: 
Uređaj za generiranje rekonstruiranog bloka, koji sadrži:
The valve according to Claim 6, characterized in that said perforated wall (36) is formed with a series of micro-slits (38) separated by intermediate septa (39). 
Ventil prema patentnom zahtjevu 6, naznačen time da je navedena perforirana stijenka (36) oblikovana s nizom mikroproreza (38) odvojenih posrednim pregradama (39).
a light chain variable region comprising SEQ ID NO:76. 
varijabilno područje lakog lanca KV1 od SEQ ID NO:76.
A pharmaceutical composition comprising the antibody of any one of claims 1, 2 or 10 to 15, or obtained by the method of claim 9 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća protutijelo prema bilo kojem od zahtjeva 1, 2 ili 10 do 15, ili protutijelo koje se može dobiti putem postupka prema zahtjevu 9, i farmaceutski prihvatljiv nosač.
The antibody for the use of claim 20 or the use of the antibody according to claim 19, wherein said disorder is a haematological malignancy or an autoimmune disease. 
Uporaba prema zahtjevu 19, ili protutijelo za uporabu prema zahtjevu 20, naznačena ili naznačeno time, da spomenuti poremećaj je hematološki maligni poremećaj ili autoimuna bolest.
The antibody for use or the use of the antibody according to claim 21, wherein said haematological malignancy is B-cell lymphoma, non-Hodgkin's lymphoma, or B-cell chronic lymphocytic leukaemia. 
Protutijelo za uporabu prema zahtjevu 21, naznačeno time, da navedeni hematološki maligni poremećaj je limfom B-stanice, non-Hodgkin-limfom, ili kronična limfocitna leukemija B-stanice.
An isolated antibody for use in treating cancer according to claim 9 wherein said cancer is hematological cancer and is selected from the group consisting of multiple myeloma, chronic lymphoblastic leukemia, chronic lymphocytic leukemia, plasma cell leukemia, acute myeloid leukemia, chronic myeloid leukemia, B-cell lymphoma, and Burkitt's lymphoma. 
Izolirano protutijelo za uporabu u liječenju raka prema zahtjevu 9 naznačeno time da navedeni rak je hematološki rak i odabran je iz skupine koju čine multipli mijelom, kronična limfoblastična leukemija, kronična limfocitna leukemija, leukemija stanica plazme, akutna mijeloidna leukemija, kronična mijeloidna leukemija, limfom B stanica, i Burkittov limfom.
A composition comprising a fusion molecule comprising: 
Sastav, naznačen time, da obuhvaća fuzijsku molekulu koja obuhvaća sljedeće:
TACI extracellular domain or fragment thereof which binds BlyS; and 
izvanstanična domena TACI ili njezin fragment koji veže BLyS; i
a human immunoglobulin-constant domain, for use in the treatment of SLE in a patient with mild-to-moderate SLE, wherein said dosage is from about 1 to about 10 mg/kg and said administration occurs at weekly intervals for multiple weeks after the initial dose. 
konstantna domena ljudskog imunoglobulina, za uporabu u liječenju SLE kod pacijenta koji ima blagu do umjerenu SLE, pri čemu navedena doza iznosi od oko 1 mg/kg do oko 10 mg/kg i navedena primjena se provodi u tjednim intervalima za više tjedana nakon inicijalne doze.
A composition for use according to claim 1, wherein said TACI extracellular domain has a sequence comprising SEQ ID NO:1, or wherein said TACI extracellular domain is at least 50% identical to SEQ ID NO:1. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da navedena izvanstanična domena TACI ima sekvencu koja obuhvaća SEQ ID NO: 1, ili pri čemu je navedena izvanstanična domena TACI najmanje 50% identična sa SEQ ID NO: 1.
A composition for use according to claim 1, wherein said fusion molecule is atacicept. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da navedena fuzijska molekula je atacicept.
A composition for use according to claim 1, wherein said composition is administered in amount of about 1 to about 9 mg/kg. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da se navedeni sastav primjenjuje u količini od oko 1 mg/kg do oko 9 mg/kg.
A composition for use according to Claim 1, wherein said TACI extracellular domain has a sequence comprising amino acids 30-110 of SEQ ID NO:1. 
Sastav za uporabu prema zahtjevu 1, naznačen time, da navedena izvanstanična domena TACI ima sekvencu koja obuhvaća aminokiseline 30-110 od SEQ ID NO: 1.
A composition for use according to claim 8, wherein said second medicament is selected from the group consisting of: NSAIDS, anti-malarials, corticosteroids, immunosuppressives, IVIg, DHEA, and thalidomide. 
Sastav za uporabu prema zahtjevu 8, naznačen time, da je navedeni drugi lijek odabran iz skupine koju čine: NSAIDi, anti-malarici, kortikosteroidi, imunosupresivi, IVlg, DHEA i talomid.
A composition for use according to any preceding claim, wherein said composition is administered subcutaneously, orally or intravenously. 
Sastav za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da se navedeni sastav primjenjuje subkutano, oralno ili intravenozno.
A composition for use according to any preceding claim, in which the patient is a human. 
Sastav za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da pacijent je čovjek.
A composition for use according to claim 4 wherein said administration is subcutaneous, and said dosage is 3 mg/kg. 
Sastav za uporabu prema zahtjevu 4, naznačen time, da navedena primjena je subkutana, a navedena doza je 3 mg/kg.
A composition for use according to Claim 12 or 13, wherein said administration occurs at weekly intervals for four weeks after the initial dose. 
Sastav za uporabu prema zahtjevu 12 ili 13, naznačen time, da navedena primjena slijedi u tjednim intervalima u vremenu od četiri tjedna nakon inicijalne doze.
a light chain variable region comprising SEQ ID NO:10. 
varijabilnu regiju lakog lanca koja sadrži SEQ ID NO:10; i
each Yi is a beta-aggregating sequence independently selected from a stretch of 6 to 16 contiguous amino acids, at least 50% of which are hydrophobic amino acids, and in which at least one aliphatic residue or F is present, and if only one aliphatic residue or F is present, at least one, and preferably at least two, other residues are selected from Y, W, A, M and T; and in which no more than 1, and preferably none, P, R, K, D or E residue is present, and wherein at least one Yi is a stretch identical to or differing with no more than one amino acid substitution from a contiguous stretch of amino acids naturally occurring in a protein; and 
svaki Yi je beta-agregacijska sekvenca neovisno odabrana iz slijeda 6 do 16 susjednih aminokiselina od kojih je barem 50% hidrofobnih aminokiselina i u kojoj je prisutan najmanje jedan alifatski ostatak ili F, i ako je je prisutan najmanje jedan alifatski ostatak ili F, barem jedan, a poželjno najmanje dva druga ostatka odabrani su od Y, W, A, M i T; i u kojem nije prisutan više od 1, a poželjno nijedan ostatak P, R, K, D ili E, i pri čemu je barem jedan Yi slijed identičan ili različit od ne više od jedne supstitucije aminokiseline iz susjednog proteina aminokiselina koje se prirodno pojavljuju u proteinu; i
each Zi is a linker and Zn is independently selected from a linker or nothing; wherein the molecule is capable of binding to, inducing aggregation of or down-regulating the biological function of said protein and wherein binding of the molecule to said protein, aggregation of said protein or downregulation of the biological function of said protein in a subject is therapeutically useful; 
svaki Zi je linker i Zn se neovisno bira između linkera ili ništa; pri čemu se molekula može vezati, inducirajući agregiranje ili spuštanje regulacije biološke funkcije navedenog proteina, te pri čemu je vezanje molekule na navedeni protein, agregacija navedenog proteina ili smanjenje regulacije biološke funkcije navedenog proteina kod subjekta terapeutski korisno; za upotrebu kao lijek.
for use as a medicament. The molecule of claim 3, wherein the expression or overexpression of said protein is associated with or causative of a disease, for use in treatment or prevention of said disease. 
Molekula u skladu s patentnim zahtjevom 3, naznačena time, da je ekspresija ili prekomjerena ekspresija navedenog proteina povezana sa ili uzrokuje bolest, za uporabu u liječenju ili prevenciji navedene bolesti.
The molecule of claim 3, wherein binding of the molecule to said protein, aggregation of said protein or downregulation of the biological function of said protein in a subject is therapeutically useful in cancer, such as wherein the expression or overexpression of said protein is associated with or causative of cancer, for use in treatment of cancer. 
Molekula u skladu s patentnim zahtjevom 3, naznačena time, da je vezanje molekule na navedeni protein, agregacija navedenog proteina ili smanjenje regulacije biološke funkcije navedenog proteina kod subjekta terapeutski korisno kod raka, kao primjerice kada je ekspresija ili prekomjerna ekspresija navedenog proteina povezana s ili uzrokuje rak, za upotrebu u liječenju raka.
The molecule of claim 3, wherein binding of the molecule to said protein, aggregation of said protein or downregulation of the biological function of said protein in a subject is therapeutically useful in AMD, such as wherein the expression or overexpression of said protein is associated with or causative of AMD, for use in treatment of AMD. 
Molekula u skladu s patentnim zahtjevom 3, naznačena time, da je vezanje molekule na navedeni protein, agregacija navedenog proteina ili smanjenje regulacije biološke funkcije navedenog proteina kod subjekta terapeutski korisno u AMD-u, kao primjerice kada je ekspresija ili prekomjerna ekspresija navedenog proteina povezana s ili uzrokuje AMD-a, za upotrebu u liječenju AMD-a.
The molecule of claim 3, wherein binding of the molecule to said protein, aggregation of said protein or downregulation of the biological function of said protein in a subject is therapeutically useful in inflammatory disease, such as wherein the expression or overexpression of said protein is associated with or causative of inflammatory disease, for use in treatment of inflammatory disease. 
Molekula u skladu s patentnim zahtjevom 3, naznačena time, da je vezanje molekule na navedeni protein, agregacija navedenog proteina ili smanjenje regulacije biološke funkcije navedenog proteina kod subjekta terapeutski korisno u upalnim bolestima, kao primjerice kada je ekspresija ili prekomjerna ekspresija navedenog proteina povezana s ili uzrokuje upalnu bolest, za upotrebu u liječenju upalne bolesti.
The molecule for use of claim 8 or the method of claim 9, wherein the pathogen is a viral organism. 
Molekula za uporabu u skladu s patentnim zahtjevom 8 ili postupak u skladu s patentnim zahtjevom 9, naznačena time, da je patogen virusni organizam.
A method to screen for new inhibitory and/or detection compounds, comprising the steps of: 
Postupak za ispitivanje novih spojeva za inhibiciju i / ili detekciju, naznačen time, da obuhvaća korake:
synthesizing a molecule of the following structure: (X2i-1-Yi-X2i-Zi)n, wherein: 
sintezu molekule slijedeće strukture: (X2i-1-Yi-X2i-Zi)n, pri čemu:
each Yi is a beta-aggregating sequence independently selected from 6 to 16 contiguous amino acids, at least 50% of which are hydrophobic amino acids, and in which at least one aliphatic residue or F is present, and if only one aliphatic residue or F is present, at least one, and preferably at least two, other residues are selected from Y, W, A, M and T; and in which no more than 1, and preferably none, P, R, K, D or E residue is present, and wherein at least one Yi is a stretch identical to or differing with no more than one amino acid substitution from a contiguous stretch of amino acids naturally occurring in the protein identified in step a); and 
svaki Yi je beta-agregacijska sekvenca neovisno odabrana između 6 do 16 susjednih aminokiselina od kojih je barem 50% hidrofobnih aminokiselina i u kojima je prisutan najmanje jedan alifatski ostatak ili F, i ako je je prisutan najmanje jedan alifatski ostatak ili F, najmanje jedan, a poželjno najmanje dva od ostalih ostataka odabrani su od Y, W, A, M i T; i u kojem nije prisutan više od 1, a poželjno ni jedan P, R, K, D ili E ostatak, i pri čemu je barem jedan Yi slijed identičan ili različit od ne više od jedne supstitucije aminokiselina iz susjednog proteina aminokiselina koje se prirodno pojavljuju u proteinu identificiranom u koraku a); i
assessing the function and/or aggregation of the protein. 
procjenu funkcije i / ili agregacije proteina.
contacting a sample suspected of containing the protein with a molecule of the following structure: (X2i-1-Yi-X2i-Zi)n, wherein: 
dodavanje uzorka za kojeg se sumnja da sadržava protein s molekulom slijedeće strukture: (X2i-1-Yi-X2i-Zi)n, pri čemu:
detecting the presence of the molecules reacted with the protein. 
detektiranje prisutnosti molekula koje su reagirale s proteinom.
The method of claim 16, wherein the at least one Yi which is identical to or differs with no more than one amino acid substitution from the contiguous stretch of amino acids naturally occurring in the protein to be detected is unique to said protein in said sample. 
Postupak u skladu s patentnim zahtjevom 16, naznačen time, da je barem jedan Yi koji je identičan ili se razlikuje od ne više od jedne aminokiselinske supstitucije iz susjednog proteina aminokiselina koje se prirodno pojavljuju u proteinima koji se detektiraju, jedinstven za navedeni protein u navedenom uzorku.
The method of claim 16 or 17, wherein the molecule comprises a detectable label, and the detecting in step b) is through detection of the detectable label. 
Postupak u skladu s patentnim zahtjevom 16 ili 17, naznačen time, da molekula sadržava detektabilnu oznaku, a detekcija u koraku b) provodi se detekcijom detektabilne oznake.
The method of claim 19, wherein at least two different molecules capable of binding to, inducing aggregation of or down-regulating the biological function of two different proteins to be detected are provided on the solid support. 
Postupak u skladu s patentnim zahtjevom 19, naznačen time, da su na krutoj podlozi najmanje dvije različite molekule sposobne za vezanje, induciranje agregacije ili smanjenje biološke funkcije dvaju različita proteina.
wherein the molecule is capable of binding to, inducing aggregation of or down-regulating the biological function of the protein to be detected; 
pri čemu se molekula može vezati, inducirajući agregiranje ili spuštanje regulacije biološke funkcije proteina koji se detektira;
detecting the presence of the molecules reacted with the protein. 
detektiranje prisutnosti molekula reagiranih s proteinom.
wherein the molecule is capable of down-regulating the biological function of said protein. 
pri čemu molekula može smanjiti biološku funkciju navedenog proteina.
A cement -based photocatalytic composition, which comprises: 
Fotokatalitički sastav zasnovan na cementu koji sadrži:
from 0.05 to 5% by weight of at least one superfluidizing agent; 
od 0,05 do 5 % po masi barem jednog sredstva za superfluidiziranje;
the Portland cement binder is from 20 to 50% by weight; 
Portland vezivo cementa je od 20 do 50% po masi;
the at least one superfluidizing agent is from 0.1 to 2% by weight; 
barem jedno sredstvo za superfluidiziranje je od 0,1 do 2% po masi;
Photocatalytic composition according to claims 1 or 2, wherein the photocatalytic titanium dioxide has a granulometry such that at least 95% by weight has a dimension not higher than 50 nm. 
Fotokatalitički sastav prema patentnom zahtjevu 1 ili 2, pri čemu fotokatalitički titanij dioksid ima granulometriju takvu da barem 95% po masi ima dimenziju ne veću od 50 nm.
Photocatalytic composition according to claim 3, wherein the photocatalytic titanium dioxide has a granulometry such that at least 95% by weight has a dimension not higher than 20 nm. 
Fotokatalitički sastav prema patentnom zahtjevu 3, pri čemu fotokatalitički titanij dioksid ima granulometriju takvu da barem 95% po masi ima dimenziju ne veću od 20 nm.
Photocatalytic composition according to any of claims 1 to 4, wherein the photocatalytic titanium dioxide is in admixture with a non-photocatalytic titanium dioxide. 
Fotokatalitički sastav prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je fotokatalitički titanij dioksid u smjesi s nefotokatalitičkim titanij dioksidom.
Photocatalytic composition according to claim 7, wherein the first calcareous filler (e) is in the form of particles of which not more than 5% by weight has a dimension not greater than 20 µm. 
Fotokatalitički sastav prema patentnom zahtjevu 7, pri čemu je prvo vapnenačko punilo (e) u obliku čestica od kojih ne više od 5% po masi ima dimenziju ne veću od 20 µm.
Photocatalytic composition according to claim 9, wherein the calcareous fillers (e) and (f) are present in a weight ratio (e)/(f) from 0.5 to 1.5. 
Fotokatalitički sastav prema patentnom zahtjevu 9, pri čemu su vapnenačka punila (e) i (f) prisutna u masenom omjeru (e) / (f) od 0,5 do 1,5.
Photocatalytic composition according to any one of the preceding claims, wherein the supported silane (g) is in the form of particles of which at least 95% by weight has a dimension not greater than 100 µm, preferably not greater than 80 µm. 
Fotokatalitički sastav prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je podržani silan (g) u obliku čestica od kojih barem 95% po masi ima dimenziju ne veću od 100 µm, poželjno ne veću od 80 µm.
Photocatalytic composition according to anyone of the preceding claims, further comprising: (i) at least one salt of a long chain carboxylic acid. 
Fotokatalitički sastav prema bilo kojem od prethodnih patentnih zahtjeva koji nadalje sadrži: (i) barem jednu sol karboksilne kiseline dugog lanca.
Use according to claim 14, wherein water is added to the photocatalytic composition in a predetermined proportion, by mixing until a homogeneous and fluid product is obtained. 
Uporaba prema patentnom zahtjevu 14, pri čemu se voda dodaje fotokatalitičkom sastavu u predodređenom udjelu, miješanjem dok se ne dobije homogeni i tekući proizvod.
Use according to anyone of claims from 14 to 16, wherein, after application and drying, the photocatalytic composition forms a coating layer having a thickness from 0.05 mm to 1 mm, preferably from 0.1 to 0.5 mm. 
Uporaba prema bilo kojem od patentnih zahtjeva od 14 do 16, pri čemu nakon primjene i sušenja, fotokatalitički sastav tvori sloj premaza koji ima debljinu od 0,05 mm do 1 mm, poželjno od 0,1 do 0,5 mm.
Use of a cement-based photocatalytic composition according to any one of the claims from 1 to 13, for coating surfaces made of metal, wood or plastic material, e.g. 
Uporaba fotokatalitičkog sastava zasnovanog na cementu prema bilo kojem od patentnih zahtjeva od 1 do 13, za premazivanje površina od metala, drva ili plastičnog materijala, npr.
The compound of claim 1, wherein the compound is selected from the group consisting of: and or a pharmaceutically acceptable salt thereof. 
, ili njegova farmaceutski prihvatljiva sol. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira iz skupine koju čine:
The compound of claim 1, wherein the compound is selected from the group consisting of: and or a pharmaceutically acceptable salt thereof. 
ili njihove farmaceutski prihvatljive soli. Spoj u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira iz skupine koju čine:
detecting echoes propagating in the axle (100) and analyzing the echoes to identify possible defects or discontinuities (B). 
detektiranja odjeka koji se šire osovinom (100) i njihovog analiziranja kako bi se prepoznalo moguće kvarove ili prekide (B).
rotating the probe at a speed lower than, or equal to, 30° per second. 
zakretanja sonde brzinom manjom od, ili jednaka, 30° u sekundi.
Use of the composition according to any of the previous claims as an additive in the manufacture of glass containers. 
Primjena kompozicije prema bilo kojem od prethodnih patentnih zahtjeva kao aditiva u proizvodnji staklenih posuda.
To add the tetrachloride of tin anhydrous to the mixture obtained in the step c) 
Dodati tetraklorid bezvodnog kositra u smjesu dobivenu u koraku a), i po izboru,